Orange Book product · Generic (ANDA)
DEFERASIROX
DEFERASIROX
At a glance
May 17, 2024
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 17, 2024
2 yr 1 mo ago
Today
Pharmaceutical detail
Active ingredient
DEFERASIROX
Strength
125MG
Dosage form
TABLET, FOR SUSPENSION
Route
ORAL
TE code
Not listed
Application
ANDA 206585
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of DEFERASIROX
- 2017JADENU SPRINKLEBrand (NDA)
NDA 207968 · NOVARTIS
- 2015JADENUBrand (NDA)
NDA 206910 · NOVARTIS PHARMS CORP
- 2005EXJADEBrand (NDA)
NDA 021882 · NOVARTIS
- 2025DEFERASIROXGeneric (ANDA)
ANDA 215137 · AUROBINDO PHARMA
- 2025DEFERASIROXGeneric (ANDA)
ANDA 211660 · JUBILANT GENERICS
- 2024DEFERASIROXGeneric (ANDA)
ANDA 209426 · TORRENT
- 2024DEFERASIROXGeneric (ANDA)
ANDA 213146 · PHARMOBEDIENT
- 2024DEFERASIROXGeneric (ANDA)
ANDA 211395 · PHARMOBEDIENT
- 2023DEFERASIROXGeneric (ANDA)
ANDA 214474 · AUROBINDO PHARMA LTD
- 2023DEFERASIROXGeneric (ANDA)
ANDA 216229 · ANNORA PHARMA
- 2022DEFERASIROXGeneric (ANDA)
ANDA 207124 · TEVA PHARMS USA
- 2022DEFERASIROXGeneric (ANDA)
ANDA 214650 · MSN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
